Extramedullary hematopoiesis in cancer
Extramedullary hematopoiesis in cancer"
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
ABSTRACT Hematopoiesis can occur outside of the bone marrow during inflammatory stress to increase the production of primarily myeloid cells at extramedullary sites; this process is known as
extramedullary hematopoiesis (EMH). As observed in a broad range of hematologic and nonhematologic diseases, EMH is now recognized for its important contributions to solid tumor pathology
and prognosis. To initiate EMH, hematopoietic stem cells (HSCs) are mobilized from the bone marrow into the circulation and to extramedullary sites such as the spleen and liver. At these
sites, HSCs primarily produce a pathological subset of myeloid cells that contributes to tumor pathology. The EMH HSC niche, which is distinct from the bone marrow HSC niche, is beginning to
be characterized. The important cytokines that likely contribute to initiating and maintaining the EMH niche are KIT ligands, CXCL12, G-CSF, IL-1 family members, LIF, TNFα, and CXCR2.
Further study of the role of EMH may offer valuable insights into emergency hematopoiesis and therapeutic approaches against cancer. Exciting future directions for the study of EMH include
identifying common and distinct EMH mechanisms in cancer, infectious diseases, and chronic autoimmune diseases to control these conditions. SIMILAR CONTENT BEING VIEWED BY OTHERS SPLENIC RED
PULP MACROPHAGES PROVIDE A NICHE FOR CML STEM CELLS AND INDUCE THERAPY RESISTANCE Article Open access 26 September 2022 LYMPHOID CLONAL HEMATOPOIESIS: IMPLICATIONS FOR MALIGNANCY, IMMUNITY,
AND TREATMENT Article Open access 04 January 2023 MADE TO ORDER: EMERGENCY MYELOPOIESIS AND DEMAND-ADAPTED INNATE IMMUNE CELL PRODUCTION Article 11 March 2024 INTRODUCTION Hematopoiesis is
the continuous process by which blood and immune cells are produced by the actions of hematopoietic stem cells (HSCs). Thought to be organized similarly to an elevated water source draining
into a branching system of rivers, HSCs can continue to self-renew and differentiate to produce mature differentiated cells, including red blood cells, T-cell lineages, B-cell lineages,
monocyte lineages, and neutrophils. A critical component of hematopoiesis is the niche that regulates HSC self-renewal and differentiation, which is crucial for hematopoietic output. The
niche includes both hematopoietic and nonhematopoietic lineages that perform unique but sometimes overlapping roles. While occurring primarily in the bone marrow of adult animals,
hematopoiesis can occur in extramedullary sites during times of organismal stress to increase or sustain hematopoietic output, a phenomenon known as extramedullary hematopoiesis (EMH). In
cancer, EMH is increasingly recognized as a mechanism by which cancer cells generate a favorable immune environment for growth. For example, tumor cells can utilize EMH to produce
immunosuppressive hematopoietic subsets. Cancer is a major health concern in the United States of America and globally. In the United States, cancer is the second leading cause of death and
costs more to treat than any other disease1. Like other chronic inflammatory pathologies, including arthritis and myocardial infarction, solid tumors enhance the production of myeloid cells,
termed myelopoiesis, to further their own growth at the expense of their host2,3,4. In part, this increased myelopoiesis leads to a high ratio of neutrophils to lymphocytes in the
peripheral blood, which is correlated with poor survival in breast, colon, pancreatic, and gastric cancer patients and in a systematic review of all cancer types5,6,7,8. As immune-based
cancer therapeutics become more widely used, attention has turned to modulating myeloid cells in the tumor microenvironment to improve their efficacy9. One potential avenue is to target
their production at the extramedullary hematopoietic site. Here, we review the role of EMH in cancer and other inflammatory conditions and the proteinaceous factors contributing to EMH in
adults. Moreover, we discuss the hematopoietic niche in various hematopoietic organs to deepen the understanding of the unique contributions of EMH to physiological and pathological
outcomes. EMH IN CANCER EMH refers to the expansion of blood cells in the extramedullary sites of a mature animal in response to an altered organismal state. EMH does not include
hematopoiesis in organs such as the thymus at homeostasis and in any organ during development. There are three general processes that induce EMH: (1) trapping of proliferative hematopoietic
progenitors in the spleen during hyposplenism; (2) impairment of hematopoietic capacity in the bone marrow due to damage or myelophthisis; and (3) abnormal levels of circulating factors with
extramedullary hematopoietic capabilities10. Although the most common organs involved in EMH are the spleen, liver, and lymph nodes, organs as diverse as the skin, pleura, adrenal gland,
and pancreas have demonstrated EMH activity11,12,13. For factor-induced EMH, hematopoiesis-active cytokines and pathogen-associated molecular patterns, including G-CSF, GM-CSF, IL-3, and
IL-6:sIL-6R complexes, as well as lipopolysaccharide and Pam3CSK4, respectively, have been shown to play roles in stimulating EMH14,15,16,17. Some instances of EMH induced by these factors
have marked effects. Subcutaneously injected human IL-3 was reported to induce cutaneous hematopoiesis with trilineage potential at the injection site in cynomolgus monkeys17. One patient
was reported to have trilineage cutaneous hematopoiesis following G-CSF therapy to treat myelofibrosis18. The role of EMH in cancer is a rapidly growing research focus. EMH is associated
primarily with hematologic cancers but can also occur in patients with breast, lung, renal, colon, gastric, pancreatic, or prostate cancer4,11,13,19. In particular, splenic EMH has been
recognized for more than 30 years in the context of human solid tumors with or without bone marrow metastases20. The presence of EMH is potentially important for cancer treatment because EMH
preferentially induces the production of myeloid cells. In the context of cancer, increased myeloid cells are recognized as having a negative impact on survival. A high ratio of neutrophils
to lymphocytes in the peripheral blood was correlated with poor prognosis in a systematic review of all cancer types, and in pancreatic, colon, breast, and gastric cancers
individually5,6,7,8. In a case series on EMH, Bao et al.11 reported that breast cancer was the most common solid cancer reported with EMH, 7.1% of all patients had confirmed EMH in the
spleen, and 24% of patients had splenomegaly, which is clinically associated with splenic EMH. The first mouse model of splenic EMH in the context of solid tumors was created by
Cortez-Retamozo et al.21, in which the authors demonstrated that splenic myeloid progenitors contributed directly to the tumor environment and tumor growth and that human spleens similarly
expanded myelopoietic progenitors during invasive solid tumor progression. Wu et al.22 suggested that increased circulating myelopoietic progenitors in patients with solid tumors contributed
to suppressing myeloid cell generation and the formation of an immunosuppressive tumor microenvironment. Subsequently, Wu et al.4 reported increased human hematopoietic stem and progenitor
cells (HSPCs) in the red pulp of the spleen in four separate solid tumors and demonstrated that gastric cancer patients with low levels of EMH in their red pulp have a more favorable
prognosis. Additionally, these authors found that the splenic HSPCs generated in their mouse model of hepatocellular carcinoma were myeloid-biased and showed modifications to the splenic
niche4. A more recent paper identified HSPCs within the tumor mass of human glioblastomas and revealed that their presence was associated with tumor grade23. We recently evaluated the role
of EMH specific, myeloid-expanded HSPCs and their splenic niche in EMH initiation and maintenance24. Together, these data establish a series of novel and important discoveries about the
presence and role of EMH in a diverse set of solid tumors. Furthermore, given the correlation between the increased neutrophil to lymphocyte ratio and poor prognosis in patients with solid
tumors, targeted, prospective studies to identify EMH sites and EMH-inducing factors in patients with solid tumors and concomitant peripheral myeloid skewing may be justified. EMH may not
mimic all aspects of bone marrow hematopoiesis. EMH seems to occur in humans most commonly because of a loss of hematopoietic capacity in the bone marrow, in agreement with the observation
that EMH occurs secondarily to hematologic malignancy13. When eliminating hepatosplenic hematopoiesis, the most common condition associated with EMH was myelofibrosis with myeloid
metaplasia, and the most common location was the thoracic vertebral column25. Generally, EMH is associated with myeloid- or erythroid-biased differentiation, although extrathymic T-cell
development has been reported in transgenic models26. The mobilization of HSPCs often coincides with the initiation of EMH and is important in seeding cells for this process. However, the
extent to which the proliferation of local progenitors contributes to EMH is unknown. Additionally, the various factors that induce EMH begs the question of the degree of diversity that
exists within the broad framework of EMH. Is EMH a single unified endpoint for multiple types of inflammation that broadly increase myelopoietic capacity, or do different forms of
inflammation produce distinct types of EMH? Answering this question may shed light on the contribution of EMH to various disease states. EMH AND MYELOPOIESIS Myelopoiesis, the production of
myeloid lineage cells from HSPCs, is a process that occurs during homeostasis but is also highly responsive to the organismal state27,28. The development of myeloid cells involves a complex
balance of select transcription factors throughout the differentiation process29. The transcription factors that favor myeloid differentiation include PU.1, CCAAT/enhancer binding proteins
(C/EBPα, C/EBPβ and C/EBPε), growth factor independent 1 (GFI1), and interferon-regulatory factor 8 (IRF8)30,31,32,33,34,35. PU.1 is a crucial transcriptional regulator of myeloid
differentiation, followed by IRF8, which delineates the monocyte lineage, and C/EBPα, which delineates the neutrophil lineage30,31,35. In times of organismal stress, the nature of factors
driving myelopoietic differentiation can be altered. For instance, mice lacking _Cebpb_ maintain normal granulocytopoiesis while in homeostasis but fail to induce emergency
granulocytopoiesis during challenge36. Cytokine factors, including G-CSF, GM-CSF, M-CSF, IL-1, and IL-27, can stimulate the production of myeloid cells37,38,39,40,41. The tumor
microenvironment (TME) contains a diverse population of myeloid cells similar to that generated during homoeostasis, including neutrophils, macrophages, and dendritic cells, as well as
subsets not present at homeostasis, such as myeloid-derived suppressor cells (MDSCs)42,43,44. This review will focus on granulocytic MDSCs (G-MDSCs) due to their association with solid
tumors, the ongoing study of their developmental origin, and their presumed effects on treatment outcomes and prognosis. Compared with homeostatic neutrophil subsets, G-MDSCs exhibit
positive CD84 expression in mice and humans and positive LOX1 expression in humans in addition to their functional capacity to inhibit T-, B-, and NK-cell activation44,45,46. It is important
to note that many historical studies have not separated neutrophils from tumor-associated neutrophils or neutrophils from G-MDSCs due to their similar surface phenotype and the recent
discovery of distinctive markers. Because G-MDSCs have been shown to be the most abundant neutrophil subset in the circulation and in the TME during late-stage tumor progression, unless the
cited paper specifically distinguishes neutrophils in cancer from G-MDSCs, it is reasonable to assume that these neutrophils are indeed G-MDSCs. In addition to the expansion of myelopoiesis,
changes in the cytokine milieu also impact the cellular products of myelopoiesis, most prominently, the production of G-MDSCs44. Many factors are required for stimulating emergency
granulocytopoiesis, and a secondary factor directs the polarization of G-MDSCs toward an immunoregulatory phenotype47. Two particularly important signaling pathways are the NF-κB and STAT1
and STAT3 pathways48. The factors implicated in inducing immunosuppressive activity through the NF-κB pathway include TNFα, IL-1β, and Toll-like receptor ligands, while IFNγ is most commonly
linked to STAT1 activation49,50. G-CSF may be important for inducing STAT3 activation in developing G-MSDCs51,52. Interestingly, G-CSF has also been shown to promote the development of
immunosuppressive neutrophils at the expense of dendritic cells capable of cancer immunosurveillance53,54. Together, these data implicate an extensive list of cytokines that could contribute
to the pathological myelopoiesis identified in cancer. Future research should strive to identify the factors that initiate the cascade of myelopoiesis and the relative contributions of
immune-derived and tumor-derived factors to the induction and maintenance of myelopoiesis. Additionally, these studies did not address the contribution of EMH to the induction of
pathological myelopoiesis, and emerging data suggest that EMH is an important producer of pathological G-MDSCs in the context of solid tumors. G-MDSCs are recruited into the tumor
environment through the binding of their CXCR2 receptor to CXCL1, CXCL2, and CXCL855. In keeping with its importance in the TME, high systemic CXCL8 levels in tumors increase the number of
neutrophils, presumably G-MDSCs, and recruit cells to the tumor microenvironment, reducing the efficacy of anti-PD-L1 therapy56,57. Conversely, CXCR2 deletion or the use of anti-Ly6G
antibodies in mouse models slows tumorigenesis58,59,60,61,62. Once in the TME, G-MDSCs maintain immunosuppression through the promotion of angiogenesis and metastasis and reduced
responsiveness to immune checkpoint blockade57,63,64. To promote angiogenesis, G-MDSCs have been shown to express MMP9, BV8, and VEGF65,66,67,68. G-MDSCs have also been shown to promote
metastasis by enhancing the epithelial–mesenchymal transition of tumor cells through the upregulation of hepatocyte growth factor and TGF-beta69. At the site of metastasis, G-MDSCs can
capture circulating tumor cells through neutrophil extracellular traps and surface markers59,70. The presence of granulocytes with altered phenotypes in the presence of chronically inflamed,
solid tumors has sparked investigations into the developmental processes that lead to their production and the crucial mechanistic processes that can be targeted for therapeutic
intervention. BONE MARROW HEMATOPOIETIC NICHE To understand how alterations in hematopoiesis occur during cancer, one must understand the hematopoietic niche of the bone marrow, as this
region is the primary site of hematopoiesis during homeostasis. The bone marrow HSC niche exists in a complex microanatomical environment that fosters the differentiation and self-renewal of
HSCs while also directing their response to organismal changes71,72. While many cell types have been implicated to play a role in this niche, here, we will focus on perivascular stromal
cells, endothelial cells, sympathetic nerves, and macrophages. Prominent within the bone marrow hematopoietic niche are cell types known as perivascular stromal cells, mesenchymal stem
cells, or osteoblast precursor cells, which will be collectively treated as the same cell type here, as recent evidence does not support their separation into distinct cell types. The
expression of both CXCL12 and KIT ligands distinguishes these cells from other constituents of the bone marrow niche73,74. These mesenchymal stem cells in the bone marrow most commonly
distinguished by leptin receptor, nestin, Mx1, Prx1, Osx, PDGFRα, or CD51 expression75,76,77. Initial studies also identified osteoblasts as critical components of the niche78,79. However,
when CXCL12 or KIT ligands were deleted from mature osteoblasts, no significant changes in hematopoietic lineages were observed74,77,80. This finding likely reflects the fact that
mesenchymal stem cells of the bone appear capable of differentiating into osteoblasts in vitro and were misconstrued as representing mature osteoblasts in early studies81. In fact, under
proper culture conditions, mesenchymal stem cells are capable of maintaining HSCs in vitro75,76. Endothelial cells of the bone marrow contribute multiple factors that play a role in the bone
marrow niche, including E-selectin, basic FGF, DLL1, IGFBP2, angiopoietin 1, DHH, and EGF82,83,84,85,86,87. Within the bone marrow, the vascular niche is thought to be split into an
arteriolar and a sinusoidal-megakaryocyte component. The arteriolar components were first identified as the preferential location of quiescent HSCs in the endosteal region of the bone
marrow88. In addition to endothelial cells and mesenchymal stem cells, the arteriolar niche includes sympathetic neurons and nonmyelinating Schwann cells, each with their own niche
contribution. Sympathetic neurons alter CXCL12, angiopoietin 1, KIT ligand, and VCAM-1 expression in mesenchymal stem cells through β3-adrenergic receptor signaling and thus enhance
mobilization89,90. Schwann cells contribute to the activation of TGFβ, a regulator of HSC quiescence91,92. In addition to the endothelial and mesenchymal stem cell components, the venous
sinusoidal niche also contains megakaryocytes that reduce HSC proliferation through CXCL4 and TGFβ but also promote recovery after radioablation through FGF193,94,95,96. Macrophages also
effect the bone marrow niche through their regulation of CXCL12 expression on mesenchymal stem cells97,98. The bone marrow niche also responds to a variety of signals, including circadian
rhythms, prostaglandins, pathogen-associated molecular patterns, and hormones89,99,100,101,102. Ironically, in a model of primary myelofibrosis in the bone marrow niche, the overgrowth of
mesenchymal stem cells reduces the amount of the marrow space available for hematopoietic cells103. Additionally, the hematopoietic niche undergoes remodeling in response to myelopoietic
stimuli during aging or in patients with obesity104,105,106,107,108. Phenotypes associated with aging can be rescued by altering sympathetic signaling within the bone marrow, indicating that
sympathetic nervous system activity may play a part in age-related changes in hematopoiesis106,107. In obesity, the role of adipocytes in modulating the niche has been an important topic of
study109. However, varying effects of adipocytes on HSPC maintenance and differentiation have been reported. Initial studies linked BM with high adiposity to lower hematopoietic
output110,111. Other data have shown that BM adipose tissue is capable of producing important hematopoietic cytokines, such as KITL and CXCL12, while being able to support hematopoiesis in
vitro112,113,114. Additionally, adipocytes are recognized as contributing myeloid-biasing cytokines such as TNFα and IL-6115,116. When taken together, the components of the bone marrow niche
supply many factors, often in conflict with each other, that drive and alter continued hematopoietic function. EXTRAMEDULLARY HEMATOPOIETIC NICHE EMH is an important topic in clinical
medicine and offers numerous opportunities to further our understanding of hematopoiesis itself. One area of interest is understanding the extramedullary niche as a unique tissue that does
not necessarily mimic the bone marrow but nevertheless recapitulates the principal factors involved in hematopoietic development. However, the diverse niche components that are involved in
hematopoiesis in nonbone marrow sites are poorly characterized. While several aspects of the splenic hematopoietic niche in adult animals have been studied, comparatively few studies have
evaluated the liver, lymph node, or skin niche. In addition, EMH of the spleen is localized to sinusoids of the red pulp, where both mesenchymal stem cells and endothelial cells produce the
KIT ligand and only mesenchymal stem cells produce CXCL12117. In a liver model of EMH, CXCL12 appeared to be upregulated in sinusoidal endothelial cells118. Moreover, KIT ligand and CXCL12
double-positive cells was present within the lesion of an adult patient with nodular, cutaneous EMH119. Despite these similarities, tissue-specific differences have also been identified.
Splenic mesenchymal stem cells are leptin receptor-negative and express Tlx1120. Additionally, some supporting cell types in the spleen appear to be different from those in the bone marrow.
For instance, a decrease in NK cells in the spleen was associated with increased myeloid progenitors, suggesting that NK cells negatively regulate splenic hematopoiesis. However, some
studies support the notion that T cells in the spleen act as hematopoietic niche cells121,122. Finally, macrophages play a role in supporting erythropoiesis and hematopoiesis in the
spleen123,124,125,126. Taken together, what is known about EMH suggests that certain core factors are required for hematopoiesis in any organ and that there are organ-specific cell types or
factors that can modulate these core processes. CYTOKINES WITH EMH POTENTIAL Below, this article provides a detailed look at individual cytokines with the potential to induce hematopoiesis
and attempts to shed light on the mechanisms underlying the interaction between cancer and hematopoiesis. KIT LIGAND KIT ligand is a fundamental hematopoietic growth factor and ligand of the
receptor c-KIT127,128. KIT ligand has soluble and transmembrane forms129. Mice that lack function in both forms have severe or fatal anemia due to hematopoietic failure and pigment and germ
cell deficiencies130. Mice lacking only the transmembrane form were still anemic, lacked pigmentation in the coat and were sterile129. Furthermore, the low body weight, anemia, and bone
marrow cellularity in mice lacking transmembrane KIT ligands could not be mitigated by the overexpression of soluble KIT ligands but could be ameliorated with membrane-restricted KIT
ligands131. Conversely, overexpressing membrane-restricted KIT ligands did not rescue reduced bone marrow myeloid progenitors in mice lacking transmembrane KIT ligands, but the
overexpression of soluble KIT did131, and the number of total peripheral blood leukocytes were rescued by both131. Finally, compared to wild-type mice, mice expressing KIT ligand lacking the
main cleavage site, and therefore lacking the majority of soluble KIT ligands, did not exhibit differences in the number of hematopoietic progenitors in the bone marrow or in mature cells
in the blood132. The binding of KIT ligand to c-KIT dimerizes the receptor and activates its intrinsic tyrosine kinase activity133,134,135. The signaling characteristics vary between the
different KIT ligand forms. Soluble KIT ligand signals rapidly and transiently followed by receptor degradation, while the membrane-associated form has sustained signaling135. Compared to
soluble KIT ligands, membrane-associated KIT ligands induce longer-lasting downstream ERK1/2 and MAP kinase activity136. The inability of c-KIT to be internalized when bound to a
membrane-associated KIT ligand may cause its sustained signaling, as immobilized anti-c-KIT antibodies also exhibit sustained signaling137. These data indicate that both forms of the KIT
ligand are unique and functionally important and that the transmembrane form may play more important roles. Despite the importance of the c-KIT/KIT ligand for maintaining hematopoiesis,
c-KIT signaling is also implicated in the quiescence of HSCs138. Additionally, c-KIT has been found to enhance the signaling of the EPO receptor and the IL-7 receptor, two important
hematopoietic cytokines, as well as PDGFRα139,140,141. The KIT ligand and its receptor c-KIT clearly play crucial roles in hematopoiesis and have biological benefits befitting its
centrality. The expression of c-Kit is likely to be a critical player in EMH, and studies investigating its regulation in the context of EMH are needed. CXCL12 CXCL12 is a pleotropic
chemokine that plays various roles in development, hematopoiesis, inflammation, and injury repair. In hematopoiesis, CXCL12 is considered the major cytokine produced by the stem cell niche
to retain HSPCs in the niche142,143. CXCL12 belongs to the CXC family of chemokines. Structurally, CXC family members have two conserved N-terminal cysteine residues that are separated by
one variable residue, and these chemokines signal primarily through GPCRs144,145 The receptor predominantly recognized for binding CXCL12 is CXCR4, while binding to ACKR3 also
occurs146,147,148,149,150. CXCR4 knockout animals die perinatally due to a combination of hematopoietic, neurogenic, vascular, and cardiogenic defects151. In contrast, ACKR3 knockout mice
still die perinatally but exhibit normal hematopoiesis152,153. Signaling through CXCR4 is complicated and involves the activation of various Gα proteins, leading to the activation of the
MAPK, PLC, and PI3K pathways154,155. Additionally, G protein-independent signaling pathways were identified. Although JAK-STAT signaling in CXCL12 cells has been reported156,157,158, other
evidence challenges the importance of this pathway159. Activation of signaling downstream of beta-arrestin has also been reported160,161,162. CXCL12 and its receptor CXCR4 are uniquely
functionally related in the context of hematopoiesis. However, the contribution of CXCL12 to the induction and maintenance of EMH is currently unknown, and given its role in maintaining
hematopoiesis in the bone marrow, CXCL12 may even be a counterregulatory cytokine to EMH. GRANULOCYTE COLONY-STIMULATING FACTOR Granulocyte colony-stimulating factor (G-CSF) is a cytokine
that has potent hematopoiesis activity163. G-CSF signals through the homodimeric receptor G-CSFR164. Downstream of receptor activation is signaling by the JAK-STAT pathway, particularly
through STAT3 and STAT5, which both promote proliferation, while STAT3 promotes differentiation165. G-CSF is thought to be produced primarily by stromal cells, such as fibroblasts and bone
marrow niche cells, and by activated myeloid cells166. G-CSF levels are low during homeostasis but can increase during an immune response and subsequently decrease to baseline167,168. Mice
lacking either G-CSF or its receptor have severe neutropenia but still produce small amounts of neutrophils37,169. G-CSF is also able to mobilize HSCs into circulation and establish
EMH18,170. IL-1Α AND IL-1Β The IL-1 cytokine superfamily has 11 members corresponding to 10 different receptors. Within this cytokine family, there are three subfamilies: IL-1, IL-18, and
IL-36. The unifying features of cytokines in this family include their lack of a signal peptide for secretion, cytoplasmic distribution as precursor molecules and the presence of a β-trefoil
pyramidal barrel structure composed of six two-stranded β hairpins171,172. However, IL-1 receptor antagonist differs from the other family members regarding these shared features, as it
lacks all of them. IL-1 signaling is transmitted through a trimeric complex comprised of the IL-1 receptor, the IL-1 family cytokines, and a coreceptor. When cytokines bind to primary
receptors, they recruit coreceptors, and signaling can occur on the cytoplasmic side. For receptors with Toll-IL-1 receptor domains, MyD88 and downstream NF-κB signaling are activated.
Additionally, the coreceptor can be present in a soluble form, either cleaved from the cell surface or produced by the liver. Both IL-1α and IL-1β signal through the IL-1R1 receptor and the
coreceptor IL-1R3, both of which have Toll-IL-1 receptor domains. IL-1β binds to IL-1R2 with IL-1R3 as its coreceptor. IL-1β is a prototypical IL-1 family member. It is a very potent
inflammatory molecule that plays a role in numerous diseases, including atherosclerosis and cancer173,174. IL-1β transcripts are induced by TLR ligands and by IL-1 itself. Following
translation, IL-1β is in an inactive form until it is cleaved intracellularly by proteases such as the inflammasome or extracellularly by proteases such as proteinase 3, elastase, MMP-9,
granzyme A, and mast cell chymase171,175. When recognized by HSCs, IL-1β stimulates proliferation and myelopoiesis39. IL-1α is considered a classic damage-associated molecular pattern that
can initiate immune responses, and its biology reflects this process176,177. IL-1α is an unusual member of the IL-1 family because it is constitutively present in epithelial and mesenchymal
cell types and does not require proteolysis for activation171. When proteolytically processed from its pro-form by proteases such as granzyme B, IL-1α becomes up to 10 times more potent178.
IL-1α also has a nuclear localization signal, and when apoptosis occurs, IL-1α traffics to the nucleus, binds to chromatin, and becomes immunologically silent. In contrast, when necrosis
occurs, IL-1α migrates to the cytoplasm, where it becomes immunologically active after the cell dies179. Given its unique biological activity, it is not surprising that IL-1α has been
reported to contribute to autoimmune disease, microbial infections, and cancer177. IL-1 signaling has recently been shown to be associated with inflammatory changes in the bone marrow niche
in that impair hematopoietic function during aging108. We recently showed that IL-1α induces TNFα expression in splenic HSPCs, which subsequently activates splenic niche activity24. In the
present study, peripheral neutrophils were decreased in tumor-bearing mice treated with an IL-1R-blocking antibody. Overall, the unique biology of IL-1β and IL-1α results in potent
initiators of nonsterile and sterile inflammation, respectively, suggesting that these family members might be potent initiators of EMH. LEUKEMIA INHIBITORY FACTOR Leukemia inhibitory factor
(LIF) is an IL-6 family member that signals through gp130 and the LIF receptor180,181. Signaling through the LIF receptor is also shared with other IL-6 family members, including OSM, CTNF,
CT-1, and CLC, although all of these cytokines have additional receptors or coreceptors for signaling180,182. Signaling downstream of LIFR:gp130 is thought to be most prominent through
JAK1, although signals can be transmitted through JAK2 and TYK2 as well183,184,185,186. JAK1 activation leads to the activation of STAT3, MAP kinase pathways, and PI3K in amounts that appear
to be cell type-specific187,188,189. LIF is best known for its ability to maintain mouse embryonic stem cells in vitro180. STAT3 and PI3 kinase both lead to enhanced self-renewal and
inhibition of differentiation in mouse embryonic stem cells, while MAP kinase activity activates differentiation190,191,192,193. LIF has several interesting functions outside of embryonic
stem cells. Mutations in LIF have been reported in infertile women, and these reports concur with the failure of blastocyst implantation in LIF knockout dams and with the observation of high
LIF expression in the endometrial glands194,195,196. In neuronal and stromal cell types, LIF also seems to increase growth while altering differentiation. Overexpression of LIF in an
injected cell line led to bone marrow fibrosis and elevated osteoblast numbers197. Similarly, osteoblasts express the LIF receptor, and LIF enhances osteoblast differentiation while
inhibiting adipocyte differentiation198. LIF overexpression by adenovirus injection enhances neural stem cell self-renewal, induces astrocyte differentiation in culture, and stimulates the
proliferation of oligodendrocyte precursor cells when overexpressed by adenovirus199,200,201. In vitro-stimulated myoblasts exhibit increased proliferation but did not differentiate into
myotubes, while LIF enhances muscle injury recovery in vivo202,203. In cancer, LIF expression has been reported in many solid tumors, such as colorectal, nasopharyngeal, skin, and breast
cancer, and has been reported to support a variety of tumor functions180,204. Although the exploration of the role of LIF is ongoing, several lines of evidence suggest that LIF is a potent
cytokine that impacts the proliferation and differentiation of stromal cells throughout the body. We recently reported that LIF is critical for the proliferation of cells localized in the
EMH niche24, highlighting how inflammatory pathologies may interact with stromal components to regulate EMH during disease. We believe that additional stromal active cytokines beyond LIF may
also play important roles in EMH. Oncostatin M is an IL-6 family cytokine related to LIF that can signal through the LIF receptor and its own oncostatin M receptor205. Oncostatin M has been
shown to promote myelopoiesis and to be active on stromal cells206,207. However, oncostatin M differs from LIF in important ways. Most importantly, oncostatin M can signal through STAT1 in
addition to STAT3205. In regard to clinical disease, oncostatin M has been widely associated with joint disease and has been found in the synovial fluid of patients with rheumatoid
arthritis208,209,210. Additionally, oncostatin M was recently identified as a biomarker of failure to respond to anti-TNFα therapy in patients with inflammatory bowel disease211. Taken
together, these data indicate that oncostatin M is an important but understudied stromal active cytokine that is associated with human pathology and expanded hematopoiesis and has
overlapping yet distinct effects compared with those of LIF. TUMOR NECROSIS FACTOR ALPHA Tumor necrosis factor alpha (TNFα) is a quintessential inflammatory cytokine with wide-ranging and
pleiotropic functions and effects212. TNFα is a trimeric member of the TNF family of cytokines. TNFα is produced as a membrane bound protein, primarily by immune cells such as monocytes and
macrophages, that can be released as a soluble factor by the action of a specific protease, TACE or TNFα-converting enzyme213. TNFα can signal through two receptors, TNFR1 and TNFR2. The
downstream signaling pathway of TNFα is complicated and involves several signaling mediators. The outcomes of TNFα signaling are highly context-dependent but can include NF-κB activation,
MAPK activation, and cell death. In the context of cancer, TNFα plays roles in nearly every stage, including tumorigenesis, tumor growth, angiogenesis, and metastasis but also has
anti-oncogenic effects and can be used as an anticancer treatment212. At the intersection of cancer and hematopoiesis, TNFα has been implicated in inducing myelopoiesis in the context of
cancer214. With this link to myelopoiesis, local TNFα has also been shown to potentially be linked to EMH in the context of cancer. CXCR2 LIGANDS CXCR2 is a GPCR chemokine receptor with a
wide repertoire of ligands that are highly conserved among vertebrates215. CXCR2 shares 77% amino acid identity with CXCR1 in humans and is positioned nearby on the same chromosome216.
Ligands that bind to CXCR2 share a glutamic acid-leucine-arginine (ELR) motif and include CXCL1-3 and CXCL5-8216. CXCR2 is classically expressed on neutrophils, including G-MDSCs, and
oligodendrocytes, although a wide selection of cells has been reported215. Upon activation of the receptor and after initiation of GPCR signaling, intracellular calcium stores are released
into the cytoplasm, and gradient chemotaxis, degranulation, and MAPK activation can occur217,218. In the context of cancer, CXCL1-3 has been found to be directly expressed on human melanoma
cells, and CXCL8 has been found to be produced by human prostate cancer cells219,220. Immune cells within the TME, such as macrophages, have also been shown to recruit G-MDSCs through CXCL2
expression60. Although not fully understood, CXCR2 ligands can mobilize HSPCs from the bone marrow despite the apparent lack of CXCR2 expression by these cells221. This ability of CXCR2
ligands to mobilize stem cells may be an important contributor to the induction of EMH. CONCLUDING REMARKS AND FUTURE PERSPECTIVES While hematopoiesis is essential for maintaining immune
system function, it is also increasingly recognized as an important contributor to organismal pathology. Here, we have provided an overview of the interaction between solid tumors and
hematopoiesis through extramedullary production of an immunosuppressive granulocyte subset and the systemic and niche factors enabling that production. Although this is still an emerging
area of interest, the study of EMH holds promise for providing a better understanding of the alterations in hematopoiesis that occur in cancer and for better therapeutic approaches to
cancer. In this review, we present studies contributing to a broad understanding of the initiation and maintenance of EMH. Initially, solid tumors or noncancerous TME cells begin to produce
CXCR2, either endogenously or through inflammation. These CXCR2 ligands recruit neutrophils to tumors while mobilizing HSPCs from the bone marrow. Cytokines are released simultaneously by
the tumor and the TME induces the stromal cells in extramedullary sites to initiate hematopoiesis. Due to the unique biology of the extramedullary niche, circulating cytokines, or both,
hematopoiesis in the extramedullary site becomes skewed toward the production of immunosuppressive granulocytes, G-MDSCs. These G-MDSCs can return to the TME via CXCR2 and support tumor
growth. This broad overview is consistent with the available data and provides multiple avenues for therapeutic development and further exploration. In addition to cancer, G-MDSCs have been
found to be involved in many chronic inflammatory pathologies, suggesting that the processes underlying EMH may operate more broadly than previously appreciated222. G-MDSCs have been
identified in human patients with viral and bacterial sepsis, where they are thought to efficiently resolve the infection223,224. Unlike their role in cancer, some studies have theorized
that G-MDSCs promote disease resolution in the proper context. In rheumatoid arthritis, G-MDSCs have been identified in the synovial fluid of humans and mouse models, where their
immunosuppressive function may be beneficial225. A study of dextran sulfate sodium (DSS)-induced colitis showed that G-MDSCs improved recovery when transplanted into mice just before the DSS
model was established226. G-MDSC administration was also able to ameliorate experimental autoimmune encephalitis (EAE) in mice227. Another study revealed that multiple sclerosis patients
with active disease had functional G-MDSCs227. The diversity of pathologies and both the beneficial and detrimental effects of G-MDSCs in various diseases suggest that controlling the
induction and elimination of EMH is a potent target for therapeutic research in a broad range of clinically relevant inflammatory diseases. The data suggest that additional extramedullary
sites outside the liver and spleen deserve study. In the case of solid tumors, several unexpected places, such as the paraspinal region, peritoneum, bronchia, adrenal gland, endometrium,
pancreas, and ureter, were also found to have EMH activity11,13. The breadth of the sites capable of conducting hematopoiesis is surprising and hints at a broader relevance of this
phenomenon than is commonly appreciated. Additionally, as has been discussed in the literature, EMH is likely to be underreported because it does not produce distinguishing features on
imaging and requires biopsy for confirmation. Moreover, clinicians are not often aware of the possibility of hematopoiesis occurring outside of the bone marrow and therefore may not be
looking for it when treating patients228. Lymph node hematopoiesis is of interest because evidence suggests that these cells are the predominant site of EMH in cancer patients11.
Conceptually, the lymph nodes and spleen share a function as organs of immune surveillance for different fluid compartments in the body, the lymph and blood, respectively. Additionally, on a
more detailed level, the microanatomical organization of the two organs also rhymes. However, one key difference in the context of solid tumors is that the lymph node exhibits an increased
load of cytokines from the tumor mass. Assuming that the lymph node stroma is as reactive as the spleen is, one would expect that lymph node hematopoiesis would be more dramatic than in the
spleen itself. However, draining lymph nodes are also common primary sites of metastasis. Therefore, tumor growth in the lymph node may obscure any ongoing hematopoiesis. The generation of
treatments that manipulate the immune system to favor anticancer immunity has been an exciting development in modern cancer therapy. Central to the understanding of anticancer immune
activation is that mutations in the cancer genome can produce novel antigens recognized by the adaptive immune system and reduce the expression of immune surveillance genes, leading to NK
cell activation229,230. Procancer immune suppression is mediated by intrinsic mechanisms preventing chronic immune activation and cancer-induced immune cell phenotypic skewing away from
activation229. These competing signals set a balance that is now being manipulated by therapeutics such as immune checkpoint inhibitors, recombinant cytokine therapy, and chimeric antigen
receptor T-cell and NK-cell therapies229,231,232,233. However, care must be taken as the overactivation of the immune system via these therapies can lead to severe side effects234,235.
Therapeutics developed with an understanding of cancer–immune interactions have been revolutionary, but progress still remains in terms of improving efficacy and minimizing side effects.
Central to improving the efficacy of immune-targeting therapeutics is local activation of the immune system, a state modulated by systemically derived myeloid cells produced by EMH. In
conclusion, emerging studies on the initiation and maintenance of EMH have highlighted how cellular products from this process alter the course of clinically important diseases such as
cancer. We look forward to future studies reporting the components of the extracellular niche and to clinical studies broadening the relevance of this pathological process to other disease
states. REFERENCES * Jemal, A., Thomas, A., Murray, T. & Thun, M. Cancer statistics, 2002. _CA Cancer J. Clin._ 52, 23–47 (2002). Article PubMed Google Scholar * Nahrendorf, M.
Myeloid cell contributions to cardiovascular health and disease. _Nat. Med._ 24, 711–720 (2018). Article CAS PubMed PubMed Central Google Scholar * Oduro, K. A. Jr. et al. Myeloid
skewing in murine autoimmune arthritis occurs in hematopoietic stem and primitive progenitor cells. _Blood J. Am. Soc. Hematol._ 120, 2203–2213 (2012). CAS Google Scholar * Wu, C. et al.
Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. _J. Clin. Invest._ 128, 3425–3438 (2018). Article PubMed PubMed Central Google
Scholar * Corbeau, I., Jacot, W. & Guiu, S. Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: a systematic review. _Cancers_ 12, 958 (2020).
Article CAS PubMed PubMed Central Google Scholar * Iwai, N. et al. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. _Sci. Rep._ 10, 1–7 (2020).
Article Google Scholar * Templeton, A. J. et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. _J. Natl Cancer Inst._ 106,
dju124 (2014). Article PubMed Google Scholar * Zhang, Y. et al. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in gastric cancer. _Medicine_ 97, e0144
(2018). Article PubMed PubMed Central Google Scholar * De Cicco, P., Ercolano, G. & Ianaro, A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to
overcome immune evasion. _Front. Immunol._ 11, 1680 (2020). Article CAS PubMed PubMed Central Google Scholar * O’Malley, D. P. Benign extramedullary myeloid proliferations. _Mod.
Pathol._ 20, 405–415 (2007). Article PubMed Google Scholar * Bao, Y. et al. Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review. _Cancer
Manag. Res._ 10, 1461 (2018). Article PubMed PubMed Central Google Scholar * Khalil, S., Ariel Gru, A. & Saavedra, A. P. Cutaneous extramedullary haematopoiesis: Implications in
human disease and treatment. _Exp. Dermatol._ 28, 1201–1209 (2019). Article PubMed Google Scholar * Fan, N., Lavu, S., Hanson, C. A. & Tefferi, A. Extramedullary hematopoiesis in the
absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients. _Blood Cancer J._ 8, 1–4 (2018). Article Google Scholar * Nagai, Y. et al. Toll-like receptors on
hematopoietic progenitor cells stimulate innate immune system replenishment. _Immunity_ 24, 801–812 (2006). Article CAS PubMed PubMed Central Google Scholar * Regan-Komito, D. et al.
GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. _Nat. Commun._ 11, 1–15 (2020). Article Google
Scholar * Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6–sIL-6R double transgenic mice. _J. Exp. Med._ 185, 755–766 (1997). Article CAS
PubMed PubMed Central Google Scholar * Khan, K. N. M. et al. Recombinant human interleukin-3 induces extramedullary hematopoiesis at subcutaneous injection sites in cynomolgus monkeys.
_Toxicol. Pathol._ 24, 391–397 (1996). Article CAS PubMed Google Scholar * Dagdas, S. et al. Unusual extramedullary hematopoiesis in a patient receiving granulocyte colony-stimulating
factor. _Acta Haematol._ 116, 198–202 (2006). Article PubMed Google Scholar * Cenariu, D. et al. Extramedullary hematopoiesis of the liver and spleen. _J. Clin. Med._ 10, 5831 (2021).
Article CAS PubMed PubMed Central Google Scholar * Conor O’keane, J., Wolf, B. C. & Neiman, R. S. The pathogenesis of splenic extramedullary hematopoiesis in metastatic carcinoma.
_Cancer_ 63, 1539–1543 (1989). Article Google Scholar * Cortez-Retamozo, V. et al. Origins of tumor-associated macrophages and neutrophils. _Proc. Natl Acad. Sci. USA_ 109, 2491–2496
(2012). Article CAS PubMed PubMed Central Google Scholar * Wu, W.-C. et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. _Proc. Natl Acad.
Sci. USA_ 111, 4221–4226 (2014). Article CAS PubMed PubMed Central Google Scholar * Lu, I.-N. et al. Tumor-associated hematopoietic stem and progenitor cells positively linked to
glioblastoma progression. _Nat. Commun._ 12, 1–16 (2021). Article Google Scholar * Barisas, D. A. et al. Tumor-derived interleukin-1α and leukemia inhibitory factor promote extramedullary
hematopoiesis. _PLoS Biol._ 21, e3001746 (2023). Article CAS PubMed PubMed Central Google Scholar * Koch, C. A., Li, C.-Y., Mesa, R. A. & Tefferi, A. Nonhepatosplenic extramedullary
hematopoiesis: associated diseases, pathology, clinical course, and treatment. In _Mayo Clinic Proceedings_. Elsevier; 2003. pp. 1223–1233. * Blais, M. È., Louis, I. & Perreault, C.
T‐cell development: an extrathymic perspective. _Immunol. Rev._ 209, 103–114 (2006). Article PubMed Google Scholar * Mitroulis, I., Kalafati, L., Hajishengallis, G. & Chavakis, T.
Myelopoiesis in the context of innate immunity. _J. Innate Immun._ 10, 365–372 (2018). Article CAS PubMed PubMed Central Google Scholar * Chiba, Y. et al. Regulation of myelopoiesis by
proinflammatory cytokines in infectious diseases. _Cell. Mol. Life Sci._ 75, 1363–1376 (2018). Article CAS PubMed Google Scholar * Rosenbauer, F. & Tenen, D. G. Transcription factors
in myeloid development: balancing differentiation with transformation. _Nat. Rev. Immunol._ 7, 105–117 (2007). Article CAS PubMed Google Scholar * Klemsz, M. J., McKercher, S. R.,
Celada, A., Van Beveren, C. & Maki, R. A. The macrophage and B cell-specific transcription factor PU. 1 is related to the ets oncogene. _Cell_ 61, 113–124 (1990). Article CAS PubMed
Google Scholar * Zhang, D.-E. et al. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. _Proc. Natl
Acad. Sci. USA_ 94, 569–574 (1997). Article CAS PubMed PubMed Central Google Scholar * Tanaka, T. et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria
killing and tumor cytotoxicity by macrophages. _Cell_ 80, 353–361 (1995). Article CAS PubMed Google Scholar * Yamanaka, R. et al. Impaired granulopoiesis, myelodysplasia, and early
lethality in CCAAT/enhancer binding protein ɛ-deficient mice. _Proc. Natl Acad. Sci. USA_ 94, 13187–13192 (1997). Article CAS PubMed PubMed Central Google Scholar * Hock, H. et al.
Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation. _Immunity_ 18, 109–120 (2003). Article CAS PubMed Google Scholar * Holtschke, T. et al.
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. _Cell_ 87, 307–317 (1996). Article CAS PubMed Google Scholar * Hirai,
H. et al. C/EBPβ is required for’emergency’granulopoiesis. _Nat. Immunol._ 7, 732–739 (2006). Article CAS PubMed Google Scholar * Lieschke, G. J. et al. Mice lacking granulocyte
colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. _Blood_ 84, 1737–1746 (1994). Article CAS
PubMed Google Scholar * Basu, S. et al. “Emergency” granulopoiesis in G-CSF–deficient mice in response to Candida albicans infection. _Blood J. Am. Soc. Hematol._ 95, 3725–3733 (2000). CAS
Google Scholar * Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. _Nat.
Cell Biol._ 18, 607–618 (2016). Article CAS PubMed PubMed Central Google Scholar * Zhan, Y. & Cheers, C. Haemopoiesis in mice genetically lacking granulocyte–macrophage colony
stimulating factor during chronic infection with Mycobacterium avium. _Immunol. Cell Biol._ 78, 118–123 (2000). Article CAS PubMed Google Scholar * Seita, J. et al. Interleukin-27
directly induces differentiation in hematopoietic stem cells. _Blood J. Am. Soc. Hematol._ 111, 1903–1912 (2008). CAS Google Scholar * Wculek, S. K. et al. Dendritic cells in cancer
immunology and immunotherapy. _Nat. Rev. Immunol._ 20, 7–24 (2020). Article CAS PubMed Google Scholar * Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C. & Allavena, P.
Tumor-associated myeloid cells: diversity and therapeutic targeting. _Cell. Mol. Immunol._ 18, 566–578 (2021). Article CAS PubMed PubMed Central Google Scholar * Veglia, F., Sanseviero,
E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. _Nat. Rev. Immunol._ 21, 485–498 (2021). Article CAS PubMed PubMed Central
Google Scholar * Alshetaiwi, H. et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. _Sci. Immunol._ 5, eaay6017 (2020).
Article CAS PubMed PubMed Central Google Scholar * Condamine, T. et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived
suppressor cells in cancer patients. _Sci. Immunol._ 1, aaf8943–aaf8943 (2016). Article PubMed PubMed Central Google Scholar * Condamine, T., Mastio, J. & Gabrilovich, D. I.
Transcriptional regulation of myeloid‐derived suppressor cells. _J. Leukoc. Biol._ 98, 913–922 (2015). Article CAS PubMed PubMed Central Google Scholar * Gabrilovich, D. I. &
Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. _Nat. Rev. Immunol._ 9, 162–174 (2009). Article CAS PubMed PubMed Central Google Scholar * Condamine, T.
& Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. _Trends Immunol._ 32, 19–25 (2011). Article CAS PubMed Google
Scholar * Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell–suppressive activity. _Blood, J. Am. Soc.
Hematol._ 111, 4233–4244 (2008). CAS Google Scholar * Waight, J. D., Hu, Q., Miller, A., Liu, S. & Abrams, S. I. Tumor-derived G-CSF facilitates neoplastic growth through a
granulocytic myeloid-derived suppressor cell-dependent mechanism. _PLoS ONE_ 6, e27690 (2011). Article CAS PubMed PubMed Central Google Scholar * Li, W. et al. G-CSF is a key modulator
of MDSC and could be a potential therapeutic target in colitis-associated colorectal cancers. _Protein Cell_ 7, 130–140 (2016). Article CAS PubMed PubMed Central Google Scholar * Meyer,
M. A. et al. Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. _Nat. Commun._ 9, 1–19 (2018). Article Google Scholar *
Casbon, A.-J. et al. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. _Proc. Natl Acad. Sci. USA_ 112, E566–E575
(2015). Article CAS PubMed PubMed Central Google Scholar * Stadtmann, A. & Zarbock, A. CXCR2: from bench to bedside. _Front. Immunol._ 3, 263 (2012). Article PubMed PubMed Central
Google Scholar * Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. _Nat. Med._ 26, 693–698 (2020). Article CAS
PubMed PubMed Central Google Scholar * Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of
immune-checkpoint inhibitors. _Nat. Med._ 26, 688–692 (2020). Article CAS PubMed PubMed Central Google Scholar * Tazawa, H. et al. Infiltration of neutrophils is required for
acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression. _Am. J. Pathol._ 163, 2221–2232 (2003).
Article CAS PubMed PubMed Central Google Scholar * Spicer, J. D. et al. Neutrophils promote liver metastasis via mac-1–mediated interactions with circulating tumor cellsneutrophil/tumor
cell adhesion promotes metastasis. _Cancer Res._ 72, 3919–3927 (2012). Article CAS PubMed Google Scholar * Shang, K. et al. Crucial involvement of tumor-associated neutrophils in the
regulation of chronic colitis-associated carcinogenesis in mice. _PLoS ONE_ 7, e51848 (2012). Article CAS PubMed PubMed Central Google Scholar * Jamieson, T. et al. Inhibition of CXCR2
profoundly suppresses inflammation-driven and spontaneous tumorigenesis. _J. Clin. Investig._ 122, 3127–3144 (2012). Article CAS PubMed PubMed Central Google Scholar * Katoh, H. et al.
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. _Cancer Cell_ 24, 631–644 (2013). Article CAS PubMed PubMed Central Google
Scholar * Wang, Y., Ding, Y., Guo, N. & Wang, S. MDSCs: key criminals of tumor pre-metastatic niche formation. _Front. Immunol._ 10, 172 (2019). Article CAS PubMed PubMed Central
Google Scholar * Li, P. et al. Lung mesenchymal cells elicit lipid storage in neutrophils that fuel breast cancer lung metastasis. _Nat. Immunol._ 21, 1444–1455 (2020). Article PubMed
PubMed Central Google Scholar * Lin, P. et al. Expansion of myeloid immune suppressor cells in Tumor-bearing host directly promotes tumor angiogenesis, tumor growth, and metastasis. _Clin.
Cancer Res._ 13, PL02-02–PL02-02 (2007). Google Scholar * Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+ Ly6C+
granulocytes. _Proc. Natl Acad. Sci. USA_ 107, 21248–21255 (2010). Article CAS PubMed PubMed Central Google Scholar * Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour
angiogenesis. _Nature_ 450, 825–831 (2007). Article CAS PubMed Google Scholar * Kusmartsev, S. et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to
tumor-induced immune suppression in renal cell carcinoma. _J. Immunol._ 181, 346–353 (2008). Article CAS PubMed Google Scholar * Toh, B. et al. Mesenchymal transition and dissemination
of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. _PLoS Biol._ 9, e1001162 (2011). Article CAS PubMed PubMed Central Google Scholar *
Cools-Lartigue, J. et al. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. _J. Clin. Investig._ 123, 3446–3458 (2013). Article CAS PubMed PubMed
Central Google Scholar * Mendelson, A. & Frenette, P. S. Hematopoietic stem cell niche maintenance during homeostasis and regeneration. _Nat. Med._ 20, 833–846 (2014). Article CAS
PubMed PubMed Central Google Scholar * Calvi, L. M. & Link, D. C. The hematopoietic stem cell niche in homeostasis and disease. _Blood J. Am. Soc. Hematol._ 126, 2443–2451 (2015). CAS
Google Scholar * Sugiyama, T., Kohara, H., Noda, M. & Nagasawa, T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell
niches. _Immunity_ 25, 977–988 (2006). Article CAS PubMed Google Scholar * Ding, L., Saunders, T. L., Enikolopov, G. & Morrison, S. J. Endothelial and perivascular cells maintain
haematopoietic stem cells. _Nature_ 481, 457–462 (2012). Article CAS PubMed PubMed Central Google Scholar * Méndez-Ferrer, S. et al. Mesenchymal and haematopoietic stem cells form a
unique bone marrow niche. _Nature_ 466, 829–834 (2010). Article PubMed PubMed Central Google Scholar * Pinho, S. et al. PDGFRα and CD51 mark human nestin+ sphere-forming mesenchymal stem
cells capable of hematopoietic progenitor cell expansion. _J. Exp. Med._ 210, 1351–1367 (2013). Article CAS PubMed PubMed Central Google Scholar * Greenbaum, A. et al. CXCL12 in early
mesenchymal progenitors is required for haematopoietic stem-cell maintenance. _Nature_ 495, 227–230 (2013). Article CAS PubMed PubMed Central Google Scholar * Zhang, J. et al.
Identification of the haematopoietic stem cell niche and control of the niche size. _Nature_ 425, 836–841 (2003). Article CAS PubMed Google Scholar * Calvi, L. et al. Osteoblastic cells
regulate the haematopoietic stem cell niche. _Nature_ 425, 841–846 (2003). Article CAS PubMed Google Scholar * Ding, L. & Morrison, S. J. Haematopoietic stem cells and early lymphoid
progenitors occupy distinct bone marrow niches. _Nature_ 495, 231–235 (2013). Article CAS PubMed PubMed Central Google Scholar * Ding, D.-C., Shyu, W.-C. & Lin, S.-Z. Mesenchymal
stem cells. _Cell Transplant._ 20, 5–14 (2011). Article PubMed Google Scholar * Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. _Nature_
386, 488–493 (1997). Article CAS PubMed Google Scholar * Kobayashi, H. et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of
haematopoietic stem cells. _Nat. Cell Biol._ 12, 1046–1056 (2010). Article CAS PubMed PubMed Central Google Scholar * Shalaby, F. et al. Failure of blood-island formation and
vasculogenesis in Flk-1-deficient mice. _Nature_ 376, 62–66 (1995). Article CAS PubMed Google Scholar * Doan, P. L. et al. Epidermal growth factor regulates hematopoietic regeneration
after radiation injury. _Nat. Med._ 19, 295–304 (2013). Article CAS PubMed PubMed Central Google Scholar * Himburg, H. A. et al. Pleiotrophin regulates the retention and self-renewal of
hematopoietic stem cells in the bone marrow vascular niche. _Cell Rep._ 2, 964–975 (2012). Article CAS PubMed PubMed Central Google Scholar * Hooper, A. T. et al. Engraftment and
reconstitution of hematopoiesis is dependent on VEGFR2-mediated regeneration of sinusoidal endothelial cells. _Cell Stem Cell_ 4, 263–274 (2009). Article CAS PubMed PubMed Central Google
Scholar * Kunisaki, Y. et al. Arteriolar niches maintain haematopoietic stem cell quiescence. _Nature_ 502, 637–643 (2013). Article CAS PubMed PubMed Central Google Scholar *
Méndez-Ferrer, S., Lucas, D., Battista, M. & Frenette, P. S. Haematopoietic stem cell release is regulated by circadian oscillations. _Nature_ 452, 442–447 (2008). Article PubMed
Google Scholar * Katayama, Y. et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. _Cell_ 124, 407–421 (2006). Article CAS PubMed
Google Scholar * Yamazaki, S. et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. _Cell_ 147, 1146–1158 (2011). Article CAS PubMed
Google Scholar * Yamazaki, S. et al. TGF-β as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. _Blood J. Am. Soc. Hematol._ 113, 1250–1256 (2009). CAS
Google Scholar * Heazlewood, S. Y. et al. Megakaryocytes co-localise with hemopoietic stem cells and release cytokines that up-regulate stem cell proliferation. _Stem Cell Res._ 11, 782–792
(2013). Article CAS PubMed Google Scholar * Bruns, I. et al. Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. _Nat. Med._ 20, 1315–1320 (2014).
Article CAS PubMed PubMed Central Google Scholar * Zhao, M. et al. Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. _Nat.
Med._ 20, 1321–1326 (2014). Article CAS PubMed Google Scholar * Olson, T. S. et al. Megakaryocytes promote murine osteoblastic HSC niche expansion and stem cell engraftment after
radioablative conditioning. _Blood J. Am. Soc. Hematol._ 121, 5238–5249 (2013). CAS Google Scholar * Chow, A. et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic
stem and progenitor cells in the mesenchymal stem cell niche. _J. Exp. Med._ 208, 261–271 (2011). Article CAS PubMed PubMed Central Google Scholar * Christopher, M. J., Rao, M., Liu,
F., Woloszynek, J. R. & Link, D. C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. _J. Exp. Med._
208, 251–260 (2011). Article CAS PubMed PubMed Central Google Scholar * Andonegui, G. et al. Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal
systemic Gram-negative bacterial infection. _J. Clin. Investig._ 119, 1921–1930 (2009). CAS PubMed PubMed Central Google Scholar * Day, R. B., Bhattacharya, D., Nagasawa, T. & Link,
D. C. Granulocyte colony-stimulating factor reprograms bone marrow stromal cells to actively suppress B lymphopoiesis in mice. _Blood J. Am. Soc. Hematol._ 125, 3114–3117 (2015). CAS Google
Scholar * Ikushima, Y. M. et al. Prostaglandin E2 regulates murine hematopoietic stem/progenitor cells directly via EP4 receptor and indirectly through mesenchymal progenitor cells. _Blood
J. Am. Soc. Hematol._ 121, 1995–2007 (2013). CAS Google Scholar * Itkin, T., Kaufmann, K. B., Gur-Cohen, S., Ludin, A. & Lapidot, T. Fibroblast growth factor signaling promotes
physiological bone remodeling and stem cell self-renewal. _Curr. Opin. Hematol._ 20, 237–244 (2013). CAS PubMed Google Scholar * Decker, M. et al. Leptin-receptor-expressing bone marrow
stromal cells are myofibroblasts in primary myelofibrosis. _Nat. Cell Biol._ 19, 677–688 (2017). Article CAS PubMed PubMed Central Google Scholar * Dykstra, B., Olthof, S., Schreuder,
J., Ritsema, M. & De Haan, G. Clonal analysis reveals multiple functional defects of aged murine hematopoietic stem cells. _J. Exp. Med._ 208, 2691–2703 (2011). Article CAS PubMed
PubMed Central Google Scholar * Sudo, K., Ema, H., Morita, Y. & Nakauchi, H. Age-associated characteristics of murine hematopoietic stem cells. _J. Exp. Med._ 192, 1273–1280 (2000).
Article CAS PubMed PubMed Central Google Scholar * Maryanovich, M. et al. Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche. _Nat. Med._ 24,
782–791 (2018). Article CAS PubMed PubMed Central Google Scholar * Ho, Y.-H. et al. Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during
premature or physiological aging. _Cell Stem Cell_ 25, 407–418. e406 (2019). Article CAS PubMed PubMed Central Google Scholar * Mitchell, C. A. et al. Stromal niche inflammation
mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. _Nat. Cell Biol._ 25, 30–41 (2023). Article CAS PubMed PubMed Central Google Scholar * Bowers, E. &
Singer, K. Obesity-induced inflammation: the impact of the hematopoietic stem cell niche. _JCI insight_ 6, e145295 (2021). Article PubMed PubMed Central Google Scholar * Naveiras, O. et
al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. _Nature_ 460, 259–263 (2009). Article CAS PubMed PubMed Central Google Scholar * Zhu, R.-J.,
Wu, M.-Q., Li, Z.-J., Zhang, Y. & Liu, K.-Y. Hematopoietic recovery following chemotherapy is improved by BADGE-induced inhibition of adipogenesis. _Int. J. Hematol._ 97, 58–72 (2013).
Article CAS PubMed Google Scholar * Mattiucci, D. et al. Bone marrow adipocytes support hematopoietic stem cell survival. _J. Cell. Physiol._ 233, 1500–1511 (2018). Article CAS PubMed
Google Scholar * Spindler, T. J., Tseng, A. W., Zhou, X. & Adams, G. B. Adipocytic cells augment the support of primitive hematopoietic cells in vitro but have no effect in the bone
marrow niche under homeostatic conditions. _Stem Cells Dev._ 23, 434–441 (2014). Article CAS PubMed Google Scholar * Corre, J. et al. Human bone marrow adipocytes support complete
myeloid and lymphoid differentiation from human CD34+ cells. _Br. J. Haematol._ 127, 344–347 (2004). Article PubMed Google Scholar * Liu, L.-F., Shen, W.-J., Ueno, M., Patel, S. &
Kraemer, F. B. Characterization of age-related gene expression profiling in bone marrow and epididymal adipocytes. _BMC Genomics_ 12, 1–18 (2011). Article Google Scholar * Miggitsch, C. et
al. Human bone marrow adipocytes display distinct immune regulatory properties. _EBioMedicine_ 46, 387–398 (2019). Article PubMed PubMed Central Google Scholar * Inra, C. N. et al. A
perisinusoidal niche for extramedullary haematopoiesis in the spleen. _Nature_ 527, 466–471 (2015). Article CAS PubMed PubMed Central Google Scholar * Mendt, M. & Cardier, J. E.
Role of SDF-1 (CXCL12) in regulating hematopoietic stem and progenitor cells traffic into the liver during extramedullary hematopoiesis induced by G-CSF, AMD3100 and PHZ. _Cytokine_ 76,
214–221 (2015). Article CAS PubMed Google Scholar * Kogame, T. et al. Presence of SCF/CXCL 12 double‐positive large blast‐like cells at the site of cutaneous extramedullary
haematopoiesis. _J. Eur. Acad. Dermatol. Venereol._ 32, e465–e466 (2018). Article CAS PubMed Google Scholar * Oda, A. et al. Niche-induced extramedullary hematopoiesis in the spleen is
regulated by the transcription factor Tlx1. _Sci. Rep._ 8, 1–16 (2018). Article Google Scholar * Broxmeyer, H. E. et al. Th1 cells regulate hematopoietic progenitor cell homeostasis by
production of oncostatin M. _Immunity_ 16, 815–825 (2002). Article CAS PubMed Google Scholar * Lee, J. H., Wang, C. & Kim, C. H. FoxP3+ regulatory T cells restrain splenic
extramedullary myelopoiesis via suppression of hemopoietic cytokine-producing T cells. _J. Immunol._ 183, 6377–6386 (2009). Article CAS PubMed Google Scholar * Chow, A. et al. CD169+
macrophages provide a niche promoting erythropoiesis under homeostasis and stress. _Nat. Med._ 19, 429–436 (2013). Article CAS PubMed PubMed Central Google Scholar * Liu, M. et al.
Macrophages support splenic erythropoiesis in 4T1 tumor-bearing mice. _PLoS ONE_ 10, e0121921 (2015). Article PubMed PubMed Central Google Scholar * Dutta, P. et al. Macrophages retain
hematopoietic stem cells in the spleen via VCAM-1. _J. Exp. Med._ 212, 497–512 (2015). Article CAS PubMed PubMed Central Google Scholar * Ulyanova, T., Phelps, S. R. &
Papayannopoulou, T. The macrophage contribution to stress erythropoiesis: when less is enough. _Blood J. Am. Soc. Hematol._ 128, 1756–1765 (2016). CAS Google Scholar * Huang, E. et al. The
hematopoietic growth factor KL is encoded by the SI locus and is the ligand of the c-kit receptor, the gene product of the W locus. _Cell_ 63, 225–233 (1990). Article CAS PubMed Google
Scholar * Fong, Y. & Blumgart, L. H. _Surgery Of The Liver And Biliary Tract_ (WB Saunders, 2000). * Brannan, C. et al. Developmental abnormalities in Steel17H mice result from a
splicing defect in the steel factor cytoplasmic tail. _Genes Dev._ 6, 1832–1842 (1992). Article CAS PubMed Google Scholar * Russell, E. S. Hereditary anemias of the mouse: a review for
geneticists. _Adv. Genet._ 20, 357–459 (1979). Article CAS PubMed Google Scholar * Kapur, R. et al. Signaling through the interaction of membrane-restricted stem cell factor and c-kit
receptor tyrosine kinase: genetic evidence for a differential role in erythropoiesis. _Blood J. Am. Soc. Hematol._ 91, 879–889 (1998). CAS Google Scholar * Tajima, Y. et al. Consequences
of exclusive expression in vivo of Kit-ligand lacking the major proteolytic cleavage site. _Proc. Natl Acad. Sci. USA_ 95, 11903–11908 (1998). Article CAS PubMed PubMed Central Google
Scholar * Qiu, F. et al. Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C
terminus. _EMBO J._ 7, 1003–1011 (1988). Article CAS PubMed PubMed Central Google Scholar * Yarden, Y. et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for
an unidentified ligand. _EMBO J._ 6, 3341–3351 (1987). Article CAS PubMed PubMed Central Google Scholar * Lev, S., Blechman, J. M., Givol, D. & Yarden, Y. Steel factor and c-kit
protooncogene: genetic lessons in signal transduction. _Crit. Rev. Oncog._ 5, 141–168 (1994). Article CAS PubMed Google Scholar * Kapur, R., Chandra, S., Cooper, R., McCarthy, J. &
Williams, D. A. Role of p38 and ERK MAP kinase in proliferation of erythroid progenitors in response to stimulation by soluble and membrane isoforms of stem cell factor. _Blood J. Am. Soc.
Hematol._ 100, 1287–1293 (2002). CAS Google Scholar * Kurosawa, K. et al. Immobilized anti-KIT monoclonal antibody induces ligand-independent dimerization and activation of Steel factor
receptor: biologic similarity with membrane-bound form of Steel factor rather than its soluble form. _Blood_ 87, 2235–2243 (1996). Article CAS PubMed Google Scholar * Thorén, L. A. et
al. Kit regulates maintenance of quiescent hematopoietic stem cells. _J. Immunol._ 180, 2045–2053 (2008). Article PubMed Google Scholar * Wu, H., Klingmüller, U., Acurio, A., Hsiao, J. G.
& Lodish, H. F. Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation. _Proc. Natl Acad. Sci. USA_ 94, 1806–1810 (1997).
Article CAS PubMed PubMed Central Google Scholar * Jahn, T. et al. Direct interaction between Kit and the interleukin-7 receptor. _Blood J. Am. Soc. Hematol._ 110, 1840–1847 (2007). CAS
Google Scholar * Zhu, M. et al. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. _Oncogene_ 26, 6386–6395 (2007). Article CAS PubMed Google
Scholar * Kim, C. H. & Broxmeyer, H. E. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell–derived factor-1, steel factor, and the
bone marrow environment. _Blood J. Am. Soc. Hematol._ 91, 100–110 (1998). CAS Google Scholar * Brightman, F. A., Leahy, D. E., Searle, G. E. & Thomas, S. Application of a generic
physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. _Drug Metab. Dispos._ 34, 94–101 (2006). Article CAS PubMed Google Scholar *
Bachelerie, F. et al. International Union of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.
_Pharmacol. Rev._ 66, 1 (2014). Article PubMed PubMed Central Google Scholar * Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. _Immunity_
12, 121–127 (2000). Article CAS PubMed Google Scholar * Oberlin, E. et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
_Nature_ 382, 833–835 (1996). Article CAS PubMed Google Scholar * Bleul, C. C. et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. _Nature_
382, 829–833 (1996). Article CAS PubMed Google Scholar * Balabanian, K. et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. _J.
Biol. Chem._ 280, 35760–35766 (2005). Article CAS PubMed Google Scholar * Burns, J. M. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and
tumor development. _J. Exp. Med._ 203, 2201–2213 (2006). Article CAS PubMed PubMed Central Google Scholar * Cruz-Orengo, L. et al. CXCR7 influences leukocyte entry into the CNS
parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. _J. Exp. Med._ 208, 327–339 (2011). Article CAS PubMed PubMed Central Google Scholar * Ma, Q. et al. Impaired
B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice. _Proc. Natl Acad. Sci. USA_ 95, 9448–9453 (1998). Article CAS PubMed PubMed
Central Google Scholar * Gerrits, H. et al. Early postnatal lethality and cardiovascular defects in CXCR7‐deficient mice. _Genesis_ 46, 235–245 (2008). Article CAS PubMed Google Scholar
* Sierro, F. et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. _Proc. Natl Acad. Sci. USA_ 104, 14759–14764
(2007). Article CAS PubMed PubMed Central Google Scholar * Rubin, J. B. Chemokine signaling in cancer: one hump or two? In _Seminars in Cancer Biology_. Elsevier; 2009. pp. 116–122. *
Busillo, J. M. & Benovic, J. L. Regulation of CXCR4 signaling. _Biochim. Biophys. Acta (BBA)-Biomembr._ 1768, 952–963 (2007). Article CAS Google Scholar * Soldevila, G. et al.
Impaired chemokine‐induced migration during T‐cell development in the absence of Jak 3. _Immunology_ 112, 191–200 (2004). Article CAS PubMed PubMed Central Google Scholar * Zhang,
X.-F., Wang, J.-F., Matczak, E., Proper, J. & Groopman, J. E. Janus kinase 2 is involved in stromal cell–derived factor-1α–induced tyrosine phosphorylation of focal adhesion proteins and
migration of hematopoietic progenitor cells. _Blood J. Am. Soc. Hematol._ 97, 3342–3348 (2001). CAS Google Scholar * Vila‐Coro, A. J. et al. The chemokine SDF‐lα triggers CXCR4 receptor
dimerization and activates the JAK/STAT pathway. _FASEB J._ 13, 1699–1710 (1999). Article PubMed Google Scholar * Moriguchi, M. et al. CXCL12 signaling is independent of Jak2 and Jak3.
_J. Biol. Chem._ 280, 17408–17414 (2005). Article CAS PubMed Google Scholar * Thelen, M. Dancing to the tune of chemokines. _Nat. Immunol._ 2, 129–134 (2001). Article CAS PubMed
Google Scholar * Sun, Y., Cheng, Z., Ma, L. & Pei, G. β-Arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation.
_J. Biol. Chem._ 277, 49212–49219 (2002). Article CAS PubMed Google Scholar * Shukla, A. K., Xiao, K. & Lefkowitz, R. J. Emerging paradigms of β-arrestin-dependent seven
transmembrane receptor signaling. _Trends Biochem. Sci._ 36, 457–469 (2011). Article CAS PubMed PubMed Central Google Scholar * Bendall, L. J. & Bradstock, K. F. G-CSF: From
granulopoietic stimulant to bone marrow stem cell mobilizing agent. _Cytokine Growth Factor Rev._ 25, 355–367 (2014). Article CAS PubMed Google Scholar * Fukunaga, R., Ishizaka-Ikeda, E.
& Nagata, S. Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. _J. Biol. Chem._ 265, 14008–14015 (1990). Article CAS PubMed Google
Scholar * Dong, F. et al. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. _J. Immunol._ 161,
6503–6509 (1998). Article CAS PubMed Google Scholar * Cornish, A. L., Campbell, I. K., McKenzie, B. S., Chatfield, S. & Wicks, I. P. G-CSF and GM-CSF as therapeutic targets in
rheumatoid arthritis. _Nat. Rev. Rheumatol._ 5, 554–559 (2009). Article CAS PubMed Google Scholar * Kawakami, M. et al. Levels of serum granulocyte colony-stimulating factor in patients
with infections. _Blood_ 76, 1962–1964 (1990). Article CAS PubMed Google Scholar * Cebon, J., Layton, J. E., Maher, D. & Morstyn, G. Endogenous haemopoietic growth factors in
neutropenia and infection. _Br. J. Haematol._ 86, 265–274 (1994). Article CAS PubMed Google Scholar * Liu, F., Wu, H. Y., Wesselschmidt, R., Kornaga, T. & Link, D. C. Impaired
production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor–deficient mice. _Immunity_ 5, 491–501 (1996). Article CAS PubMed Google Scholar *
Tamura, M. et al. Induction of neutrophilic granulocytosis in mice by administration of purified human native granulocyte colony-stimulating factor (G-CSF). _Biochem. Biophys. Res. Commun._
142, 454–460 (1987). Article CAS PubMed Google Scholar * Dinarello, C. A. Overview of the IL‐1 family in innate inflammation and acquired immunity. _Immunol. Rev._ 281, 8–27 (2018).
Article CAS PubMed PubMed Central Google Scholar * Towne, J. E. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist
(IL-36Ra) activity. _J. Biol. Chem._ 286, 42594–42602 (2011). Article CAS PubMed PubMed Central Google Scholar * Ridker, P. M. et al. Effect of interleukin-1β inhibition with
canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. _Lancet_ 390, 1833–1842 (2017). Article
CAS PubMed Google Scholar * Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. _N. Engl. J. Med._ 377, 1119–1131 (2017). Article CAS PubMed
Google Scholar * Pyrillou, K., Burzynski, L. C. & Clarke, M. C. Alternative pathways of IL-1 activation, and its role in health and disease. _Front. Immunol._ 11, 613170 (2020). Article
CAS PubMed PubMed Central Google Scholar * Kim, B. et al. The interleukin-1α precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. _Front.
Immunol._ 4, 391 (2013). Article PubMed PubMed Central Google Scholar * Malik, A. & Kanneganti, T. D. Function and regulation of IL‐1α in inflammatory diseases and cancer. _Immunol.
Rev._ 281, 124–137 (2018). Article CAS PubMed PubMed Central Google Scholar * Afonina, I. S. et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory
activity of IL-1α. _Mol. Cell_ 44, 265–278 (2011). Article CAS PubMed PubMed Central Google Scholar * Werman, A. et al. The precursor form of IL-1α is an intracrine proinflammatory
activator of transcription. _Proc. Natl Acad. Sci. USA_ 101, 2434–2439 (2004). Article CAS PubMed PubMed Central Google Scholar * Nicola, N. A. & Babon, J. J. Leukemia inhibitory
factor (LIF). _Cytokine Growth Factor Rev._ 26, 533–544 (2015). Article CAS PubMed PubMed Central Google Scholar * Metcalf, D. The unsolved enigmas of leukemia inhibitory factor. _Stem
Cells_ 21, 5–14 (2003). Article CAS PubMed Google Scholar * Houben, E., Hellings, N., Broux, B. & Oncostatin, M. an underestimated player in the central nervous system. _Front.
Immunol._ 10, 1165 (2019). Article CAS PubMed PubMed Central Google Scholar * Stahl, N. et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components.
_Science_ 263, 92–95 (1994). Article CAS PubMed Google Scholar * Rodig, S. J. et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in
cytokine-induced biologic responses. _Cell_ 93, 373–383 (1998). Article CAS PubMed Google Scholar * Takahashi, Y. et al. Leukemia inhibitory factor regulates trophoblast giant cell
differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway. _Mol. Endocrinol._ 22, 1673–1681 (2008). Article CAS
PubMed PubMed Central Google Scholar * Chung, B. M. et al. Jak2 and Tyk2 are necessary for lineage-specific differentiation, but not for the maintenance of self-renewal of mouse embryonic
stem cells. _Biochem. Biophys. Res. Commun._ 351, 682–688 (2006). Article CAS PubMed Google Scholar * Heinrich, P. C. et al. Principles of interleukin (IL)-6-type cytokine signalling
and its regulation. _Biochem. J._ 374, 1–20 (2003). Article CAS PubMed PubMed Central Google Scholar * Fahmi, A. et al. p42/p44-MAPK and PI3K are sufficient for IL-6 family
cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. _Cell. Signal._ 25, 898–909 (2013). Article CAS PubMed PubMed Central
Google Scholar * Oh, H. et al. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. _J. Biol.
Chem._ 273, 9703–9710 (1998). Article CAS PubMed Google Scholar * Niwa, H., Burdon, T., Chambers, I. & Smith, A. Self-renewal of pluripotent embryonic stem cells is mediated via
activation of STAT3. _Genes Dev._ 12, 2048–2060 (1998). Article CAS PubMed PubMed Central Google Scholar * Paling, N. R., Wheadon, H., Bone, H. K. & Welham, M. J. Regulation of
embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signaling. _J. Biol. Chem._ 279, 48063–48070 (2004). Article CAS PubMed Google Scholar * Meloche, S., Vella, F.
D., Voisin, L., Ang, S.-L. & Saba-El-Leil, M. Erk2 signaling and early embryo stem cell self-renewal. _Cell Cycle_ 3, 239–241 (2004). Article Google Scholar * Burdon, T., Stracey, C.,
Chambers, I., Nichols, J. & Smith, A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. _Dev. Biol._ 210, 30–43 (1999). Article CAS PubMed
Google Scholar * Stewart, C. L. et al. Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. _Nature_ 359, 76–79 (1992). Article CAS PubMed Google
Scholar * Giess, R., Tanasescu, I., Steck, T. & Sendtner, M. Leukaemia inhibitory factor gene mutations in infertile women. _Mol. Hum. Reprod._ 5, 581–586 (1999). Article CAS PubMed
Google Scholar * Charnock-Jones, D., Sharkey, A., Fenwick, P. & Smith, S. Leukaemia inhibitory factor mRNA concentration peaks in human endometrium at the time of implantation and the
blastocyst contains mRNA for the receptor at this time. _Reproduction_ 101, 421–426 (1994). Article CAS Google Scholar * Metcalf, D. & Gearing, D. Fatal syndrome in mice engrafted
with cells producing high levels of the leukemia inhibitory factor. _Proc. Natl Acad. Sci. USA_ 86, 5948–5952 (1989). Article CAS PubMed PubMed Central Google Scholar * Walker, E. C. et
al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. _J. Clin. Investig._ 120, 582–592 (2010). Article
CAS PubMed PubMed Central Google Scholar * Deverman, B. E. & Patterson, P. H. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and
enhances hippocampal remyelination. _J. Neurosci._ 32, 2100–2109 (2012). Article CAS PubMed PubMed Central Google Scholar * Yoshida, T., Satoh, M., Nakagaito, Y., Kuno, H. &
Takeuchi, M. Cytokines affecting survival and differentiation of an astrocyte progenitor cell line. _Dev. Brain Res._ 76, 147–150 (1993). Article CAS Google Scholar * Bauer, S. &
Patterson, P. H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. _J. Neurosci._ 26, 12089–12099 (2006). Article CAS PubMed PubMed Central Google
Scholar * Barnard, W., Bower, J., Brown, M., Murphy, M. & Austin, L. Leukemia inhibitory factor (LIF) infusion stimulates skeletal muscle regeneration after injury: injured muscle
expresses lif mRNA. _J. Neurol. Sci._ 123, 108–113 (1994). Article CAS PubMed Google Scholar * Austin, L. & Burgess, A. Stimulation of myoblast proliferation in culture by leukaemia
inhibitory factor and other cytokines. _J. Neurol. Sci._ 101, 193–197 (1991). Article CAS PubMed Google Scholar * Wu, L. et al. HIF-2α mediates hypoxia-induced LIF expression in human
colorectal cancer cells. _Oncotarget_ 6, 4406 (2015). Article PubMed PubMed Central Google Scholar * Richards, C. D. The enigmatic cytokine oncostatin m and roles in disease. _ISRN
Inflamm._ 2013, 512103 (2013). Article PubMed PubMed Central Google Scholar * Metcalfe, S. LIF in the regulation of T-cell fate and as a potential therapeutic. _Genes Immun._ 12, 157–168
(2011). Article CAS PubMed Google Scholar * Albiero, M. et al. Diabetes-associated myelopoiesis drives stem cell mobilopathy through an OSM-p66Shc signaling pathway. _Diabetes_ 68,
1303–1314 (2019). Article CAS PubMed Google Scholar * Langdon, C., Leith, J., Richards, C. D. & Smith, F. Oncostatin M stimulates monocyte chemoattractant protein‐1‐and
interleukin‐1‐induced matrix metalloproteinase‐1 production by human synovial fibroblasts in vitro. _Arthritis Rheum._ 40, 2139–2146 (1997). Article CAS PubMed Google Scholar * Hui, W.,
Bell, M. & Carroll, G. Detection of oncostatin M in synovial fluid from patients with rheumatoid arthritis. _Ann. Rheum. Dis._ 56, 184–187 (1997). Article CAS PubMed PubMed Central
Google Scholar * Cawston, T. et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. _Arthritis Rheum._ 41,
1760–1771 (1998). Article CAS PubMed Google Scholar * West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy
in patients with inflammatory bowel disease. _Nat. Med._ 23, 579–589 (2017). Article CAS PubMed PubMed Central Google Scholar * Wang, X. & Lin, Y. Tumor necrosis factor and cancer,
buddies or foes? 1. _Acta Pharmacol. Sin._ 29, 1275–1288 (2008). Article PubMed Google Scholar * Cheng, X., Shen, Y. & Li, R. Targeting TNF: a therapeutic strategy for Alzheimer’s
disease. _Drug Discov. today_ 19, 1822–1827 (2014). Article CAS PubMed Google Scholar * Al Sayed, M. F. et al. T-cell–secreted TNFα induces emergency myelopoiesis and myeloid-derived
suppressor cell differentiation in cancer. _Cancer Res._ 79, 346–359 (2019). Article CAS PubMed Google Scholar * Veenstra, M. & Ransohoff, R. M. Chemokine receptor CXCR2: physiology
regulator and neuroinflammation controller? _J. Neuroimmunol._ 246, 1–9 (2012). Article CAS PubMed PubMed Central Google Scholar * Ahuja, S. K., Özçelik, T., Milatovitch, A., Francke,
U. & Murphy, P. M. Molecular evolution of the human interleukin–8 receptor gene cluster. _Nat. Genet._ 2, 31–36 (1992). Article CAS PubMed Google Scholar * Knall, C. et al.
Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. _J. Biol. Chem._ 271, 2832–2838 (1996). Article CAS PubMed Google Scholar *
Murdoch, C. & Finn, A. Chemokine receptors and their role in inflammation and infectious diseases. _Blood J. Am. Soc. Hematol._ 95, 3032–3043 (2000). CAS Google Scholar * Luan, J. et
al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. _J. Leukoc. Biol._ 62, 588–597 (1997). Article CAS
PubMed Google Scholar * Moore, B. B. et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. _Am. J. Pathol._ 154, 1503–1512 (1999). Article CAS PubMed PubMed
Central Google Scholar * Karpova, D. et al. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. _J. Clin. Investig._ 129, 2745–2759 (2019). Article
PubMed PubMed Central Google Scholar * Sendo, S., Saegusa, J. & Morinobu, A. Myeloid-derived suppressor cells in non-neoplastic inflamed organs. _Inflamm. Regen._ 38, 1–11 (2018).
Article Google Scholar * Coudereau, R. et al. Emergence of immunosuppressive LOX‐1+ PMN‐MDSC in septic shock and severe COVID‐19 patients with acute respiratory distress syndrome. _J.
Leukoc. Biol._ 111, 489–496 (2022). Article CAS PubMed Google Scholar * De Zuani, M. et al. Human myeloid‐derived suppressor cell expansion during sepsis is revealed by unsupervised
clustering of flow cytometric data. _Eur. J. Immunol._ 51, 1785–1791 (2021). Article PubMed PubMed Central Google Scholar * Kurkó, J. et al. Identification of myeloid-derived suppressor
cells in the synovial fluid of patients with rheumatoid arthritis: a pilot study. _BMC Musculoskelet. Disord._ 15, 1–7 (2014). Article Google Scholar * Zhang, R. et al. Dextran sulphate
sodium increases splenic Gr1+ CD11b+ cells which accelerate recovery from colitis following intravenous transplantation. _Clin. Exp. Immunol._ 164, 417–427 (2011). Article CAS PubMed
PubMed Central Google Scholar * Ioannou, M. et al. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. _J.
Immunol._ 188, 1136–1146 (2012). Article CAS PubMed Google Scholar * Orphanidou-Vlachou, E., Tziakouri-Shiakalli, C. & Georgiades, C. S. Extramedullary hemopoiesis. In _Seminars in
Ultrasound, CT and MRI_. Elsevier; 2014. pp. 255–262. * Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer–immune set point. _Nature_ 541, 321–330 (2017). Article CAS
PubMed Google Scholar * Bald, T., Krummel, M. F., Smyth, M. J. & Barry, K. C. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. _Nat. Immunol._
21, 835–847 (2020). Article CAS PubMed PubMed Central Google Scholar * Gong, Y., Klein Wolterink, R. G., Wang, J., Bos, G. M. & Germeraad, W. T. Chimeric antigen receptor natural
killer (CAR-NK) cell design and engineering for cancer therapy. _J. Hematol. Oncol._ 14, 1–35 (2021). Article CAS Google Scholar * Yu, S. et al. Chimeric antigen receptor T cells: a novel
therapy for solid tumors. _J. Hematol. Oncol._ 10, 1–13 (2017). Article Google Scholar * García-Martínez, E. et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer
therapy. _Oncoimmunology_ 7, e1433982 (2018). Article PubMed PubMed Central Google Scholar * Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells:
recognition and management. _Blood J. Am. Soc. Hematol._ 127, 3321–3330 (2016). CAS Google Scholar * Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response,
resistance, and toxicity to immune checkpoint blockade. _Cell_ 184, 5309–5337 (2021). Article CAS PubMed PubMed Central Google Scholar Download references AUTHOR INFORMATION AUTHORS AND
AFFILIATIONS * Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA Derek A. G. Barisas & Kyunghee Choi Authors * Derek A. G. Barisas
View author publications You can also search for this author inPubMed Google Scholar * Kyunghee Choi View author publications You can also search for this author inPubMed Google Scholar
CORRESPONDING AUTHOR Correspondence to Kyunghee Choi. ETHICS DECLARATIONS CONFLICT OF INTEREST The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer
Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative
Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in
the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended
use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Barisas, D.A.G., Choi, K. Extramedullary hematopoiesis in cancer. _Exp Mol Med_ 56,
549–558 (2024). https://doi.org/10.1038/s12276-024-01192-4 Download citation * Received: 18 September 2023 * Revised: 21 December 2023 * Accepted: 26 December 2023 * Published: 05 March
2024 * Issue Date: March 2024 * DOI: https://doi.org/10.1038/s12276-024-01192-4 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable
link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative
Trending News
Redirecting alternative splicingAccess through your institution Buy or subscribe Signal transducer and activator of transcription 3 (STAT3) exists in tw...
This city in puebla celebrates christmas with millions of lights and other attractionsA Christmas village in Puebla may be the closest thing to a northern Christmas that exists in Mexico. From late November...
West Bank Palestinians fear Gaza-style clearance as Israel squeezes Jenin campNewsletters ePaper Sign in HomeIndiaKarnatakaOpinionWorldBusinessSportsVideoEntertainmentDH SpecialsOperation SindoorNew...
J balvin dedicates neon las vegas performance to valentina ferrer on her birthday: 'i love you'The "Vibras" were there _all_ three days (and nights)! Kicking off Latinx Heritage Month, J Balvin hosted the ...
1065 chloramphenicol kills h. Influenza more rapidly than ampicillinABSTRACT Although a combination of chloramphenicol (CHL) plus a penicillin is the inital therapy for H. influenza type B...
Latests News
Extramedullary hematopoiesis in cancerABSTRACT Hematopoiesis can occur outside of the bone marrow during inflammatory stress to increase the production of pri...
Scandals at uber and fox show dangers of letting macho cultures run wildMost of us have probably seen the video of Uber founder and CEO Travis Kalanick scolding one of his own drivers, cursing...
Google ceo met australia's prime minister after threatening to pull out its search engineIn this article * GOOGL Follow your favorite stocksCREATE FREE ACCOUNT SINGAPORE — Australian Prime Minister Scott Morri...
Jagapati Babu: Movies, Photos, Videos, News, Biography & Birthday | Times of IndiaWe use cookies and other tracking technologies to provide services while browsing the Website to show personalise conten...
Covid vaccine: which groups are being vaccinated now?"And all the time we must be vigilant and do what it takes to tackle any new variants that arise. For now, the most...